Sai Life Sciences Limited has informed the Exchange about appointment of Dr. John Pavey, Head Global PR&D as a Senior Management Personnel ( SMP ) of the Company, effective 1 April 2026 and retirement of Dr. Dean David Edney, with effect from the close of business hours on 31 March 2026.
SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sai Life Sciences has announced a leadership change in its Global Pharmaceutical R&D function. Dr. John Pavey will take over as Head – Global PR&D and Senior Management Personnel (SMP) effective 1 April 2026, replacing Dr. Dean David Edney who is retiring at the close of business on 31 March 2026. Dr. Pavey brings over two decades of global experience in CMC and chemical development, with prior senior leadership stints at Johnson & Johnson, UCB, and AstraZeneca, covering API development, regulatory approvals, and commercial supply. He holds a PhD in Organic Chemistry from the University of Liverpool and completed postdoctoral research at the University of Cambridge. The company filed this disclosure under SEBI LODR Regulation 30, confirming it is treating the change as a material managerial transition requiring exchange intimation.
This is a planned, orderly handover in a key R&D leadership role, not an abrupt exit. The incoming executive has strong global pharma credentials which should support continuity in the Global PR&D pipeline. For shareholders, this carries low governance risk and is unlikely to move the stock on its own.